Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Clinical research trials and Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies. Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies clinical trial. Participants frequently get the best healthcare available for their Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.

Home > "P" Clinical Trials Conditions > Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies



Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

For Condition: Mycosis Fungoides,Lymphoma, T-Cell,Hematologic Neoplasms
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: The purpose of this study is to determine the response rate of patients with T-cell malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin (Accutane).
Details: Retinoids have shown activity in T-cell malignancies in past studies (both isotretinoin and etretinate) with an overall response rate of about 60%. One third of those responses were complete responses. Interferon-alpha has proven efficacy in wide ranges of human malignancies including T-cell lymphomas as a single agent. A clinical trial was needed to evaluate the response rate of these two agents combined.
Eligibility:
Study Type:
  Interventional, Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Histologic proof of incurable T-Cell malignancy and not eligible for existing higher priority protocols. - Patients should not have received chmoe, immuno, hormonal, or radiation therapy within 3 weeks of entry into this study and must have recovered from acute toxic effects of prior therapy. - Life expectancy of at least 12 weeks and a ZUBROD status of /= 18 years of age. - No other current chemo, immuno, or radiotherapy allowed. - Bilirubin Total Enrollment: 60

Location and Contact Information:

M. D. Anderson Cancer Center *Recruiting*
Houston,  Texas,  77030
United States
Recruiting Susan  Pilat 713-745-3296


Additional Information:
Study ID Numbers:
  DM90-007; 
Study Start Date: May 1990
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038376

Other Mycosis Fungoides Studies:
1. HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies

2. Modified Stem Cell Transplant Procedure to Treat Patients with Blood and Immune System Cancers

3. A Safety Evaluation of Xigris in Patients with Blood Cancer who Develop Severe Infection related to Bone Marrow Transplantation.

4. Hematologic Neoplasms Study

5. Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

Related Studies:

Other Mycosis Fungoides Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

Modify your Search

  Other Mycosis Fungoides Clinical Trials
  Other Texas Clinical Trials
  Other Houston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103